Strengths
Cellares has developed the Cell Shuttle™, an advanced automated platform that significantly enhances productivity in cell therapy manufacturing.
The company boasts a 10x increase in productivity compared to conventional Contract Development and Manufacturing Organizations (CDMOs), positioning it as a leader in the industry.
Cellares offers substantial cost savings, with prices per batch being up to 50% lower than traditional CDMOs, making it an attractive option for pharmaceutical companies.
The platform has a 75% lower process failure rate, which enhances reliability and builds trust with clients in the life sciences sector.
Cellares is the first Integrated Development and Manufacturing Organization (IDMO), uniquely combining development and manufacturing capabilities to streamline processes.
The company has secured a significant $380 million deal with Bristol Myers Squibb, indicating strong financial backing and confidence from a major player in the pharmaceutical industry.
Cellares has achieved cGMP certification for its Cell Shuttle, a critical regulatory milestone that enhances its credibility and marketability.
The establishment of new facilities in strategic locations like New Jersey demonstrates Cellares' commitment to expansion and innovation in the life sciences sector.